Moderna, Inc.(MRNA)今日盘中股价大涨5.20%，引发市场广泛关注。
消息面上，FDA对其季节性流感疫苗候选产品mRNA-1010的审批决定即将公布，此前FDA咨询委员会已一致投票支持该疫苗的获益-风险特征，市场对获批的预期持续升温。此外，高盛近日将Moderna目标价从49美元大幅上调至67美元，维持中性评级，为股价估值修复提供支撑。
该股此前曾因财报前夕机构审慎预期出现下跌，本次上涨带有修复性反弹特征。公司第二季度财报即将发布，市场关注其业绩表现。
Moderna, Inc.(MRNA)今日盘中股价大涨5.20%，引发市场广泛关注。
消息面上，FDA对其季节性流感疫苗候选产品mRNA-1010的审批决定即将公布，此前FDA咨询委员会已一致投票支持该疫苗的获益-风险特征，市场对获批的预期持续升温。此外，高盛近日将Moderna目标价从49美元大幅上调至67美元，维持中性评级，为股价估值修复提供支撑。
该股此前曾因财报前夕机构审慎预期出现下跌，本次上涨带有修复性反弹特征。公司第二季度财报即将发布，市场关注其业绩表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.